Wei J, et al. - Researchers sought to ascertain the efficacy of neoadjuvant bevacizumab plus chemotherapy (BEV + CT) vs chemotherapy (CT) alone in the treatment of HER2-negative nonmetastatic breast cancer via performing a meta-analysis of randomized controlled trials. They identified 6 randomized controlled trials matching the selection criteria, yielding a total of 4,354 patients with early outcomes and 3,777 patients with late outcomes. Outcomes indicated that the 5-year disease-free survival (DFS) rate of HER2-negative breast cancer patients was significantly improved with the reception of neoadjuvant BEV + CT when compared with CT alone, but there appeared no benefit in terms of 5-year overall survival rate.